Gilead Sciences (GILD) Q3 2025 10-Q Quarterly Report
Filed: Nov 7, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Gilead Sciences (GILD) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 7, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Gilead Sciences Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • No specific quarterly revenue or YoY change data provided in the section
- • No profitability or margin figures disclosed for the quarter
- • No segment or product line performance data mentioned
- • No details on cash position, operating cash flow, or capital deployment changes
- • No updated guidance or management commentary on near-term outlook or headwinds
Risk Factors
- • New regulatory risk: FDA boxed warning (Jan 2024) on CAR T-cell therapies for secondary T-cell malignancies; impacts Yescarta, Tecartus acceptance
- • Updated pricing risk: Inflation Reduction Act effects uncertain; increased Medicare Part D discounts (10%-20%) and rebate obligations starting 2023-2025
- • Compliance risk: 340B contract pharmacy integrity initiative faces ongoing legal challenges from HHS and states; compliance and litigation remain uncertain
- • Operational risk: Supply chain/logistics risks in cell therapy—disruptions at apheresis centers or manufacturing delays could constrain commercialization
- • Financial risk: Dependence on 3 U.S. wholesalers (~90% sales) creates revenue volatility due to inventory and purchasing pattern fluctuations
Gilead Sciences Q3 2025 Quarterly FinancialsXBRL
Revenue
$7.8B
▲ +3.0% YoY▲ +9.7% QoQ
Net Income
$3.1B
▲ +143.6% YoY▲ +55.7% QoQ
Operating Margin
42.8%
▲ +3105bp YoY▲ +789bp QoQ
Net Margin
39.3%
▲ +2268bp YoY▲ +1161bp QoQ
ROE
14.2%
Total Assets
$58.5B
EPS (Diluted)
$2.43
▲ +140.6% YoY▲ +54.8% QoQ
Operating Cash Flow
$4.1B
▼ -4.7% YoY▲ +396.7% QoQ
Source: XBRL data from Gilead Sciences Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Gilead Sciences Quarterly Reports
Get deeper insights on Gilead Sciences
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.